Teva pushes limits with super tight pricing for $33.75bn buyout loan
Teva Pharmaceutical Industries “just scraped home” with very tight pricing on the $33.75bn loan it signed on Monday. Only around half the banks invited participated because margins were so tight, said a banker close to the deal.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: